Speakers’ Biographies - Harvard CFAR
Speakers’ BiographiesBruce D. WalkerDr. Bruce D. Walker is theDirector of the Ragon Institute ofMGH, MIT and Harvard, aProfessor of Medicine at HarvardMedical School, a Professor ofPractice at MIT and a HowardHughes Medical InstituteInvestigator. In addition to hisclinical duties as a board certifiedInfectious Disease specialist, hisresearch focuses on cellularimmune responses in chronic viral infections with aparticular focus on HIV. He leads an internationaltranslational clinical and basic science research effort tounderstand how some rare people who are infected withHIV, but have never been treated, can fight the virus withtheir immune system. Dr. Walker is also an AdjunctProfessor at the Nelson Mandela School of Medicine inDurban, South Africa. There he collaborates with the DorisDuke Medical Research Institute at the University ofKwaZulu-Natal and serves as a Principal Investigator in theHIV Pathogenesis Program, an initiative to study theevolution of the HIV and the immune responses effective incontrolling this virus, as well as to contribute to trainingAfrican scientists. He is a member of the SteeringCommittee for the KwaZulu-Natal Research Institute for TBand HIV (K-RITH), a 10-year initiative funded by HHMI tobuild a state of the art TB-HIV research facility at the heart ofthese dual epidemics in South Africa. Dr. Walker is also a
member of the American Academy of Arts and Sciences,American Society for Clinical Investigation (ASCI), theAmerican Association of Physicians (AAP), and the Instituteof Medicine (IOM) of the National Academy of Sciences.Douglas S. KwonDr. Douglas Kwon is aphysician scientist andDirector of ClinicalOperations at the RagonInstitute of MGH, MIT andHarvard. He has a clinicalpractice in the division ofInfectious Diseases atMassachusetts GeneralHospital. The focus of hiscurrent research is understanding the role of mucosal tissuesin HIV acquisition and disease progression. His lab is involvedin developing and applying new technologies to overcomethe technical barriers that have impeded our understandingof mucosal immunity to date. This includes the application ofnovel techniques and functional assays to assess HIV-specificimmune responses and the microbiome at mucosal sites.
Ingrid T. KatzDr. Ingrid Katz is an AssistantProfessor in Medicine atHarvard Medical School. Sheserves as an Associate Physicianin the Division of Women'sHealth and the Division ofMedical Communications, bothin the Department of Medicineat Brigham and Women'sHospital, and is a researchscientist at the Center for Global Health at MassachusettsGeneral Hospital. She obtained a B.A. from Amherst College,and a Master's in Health Science from Johns HopkinsBloomberg School of Public Health before pursuing herdegree in Medicine at University of California at SanFrancisco (graduating AOA). After completing her medicaltraining in Internal Medicine and Infectious Diseases, shereceived a Global Women's Health Fellowship to study HPVvaccine uptake among adolescents in Soweto, South Africa.Her current research focuses on factors affecting refusal toparticipate in HIV treatment programs among HIV-infected,treatment eligible adults presenting for testing.She has worked with multiple NGO's andmultinational organizations including the Population Council,UNICEF, and the World Health Organization. Dr. Katz has alsoserved as an Editorial Fellow at the New England Journal ofMedicine, and is a member of the Perspectives workinggroup. She has been the recipient of the Harvard CatalystKL2 Medical Research Investigator Training (MeRIT) Award,the Harvard Global Health Institute Travel Award, the
Eleanor and Miles Shore Award, the CROI Young InvestigatorAward, the Center for AIDS Prevention Scholar Award, andthe Burke Global Health Fellowship. She is currently PrincipalInvestigator on two NIH-funded projects in South Africa.Anthony S. FauciDirector, National Institute ofAllergy and Infectious Diseases(NIAID)Chief, NIAID Laboratory ofImmunoregulation NationalInstitutes of Health, Bethesda,MarylandAnthony S. Fauci, M.D., isdirector of the NationalInstitute of Allergy and Infectious Diseases (NIAID) at the U.S.National Institutes of Health, where he oversees anextensive research portfolio devoted to preventing,diagnosing, and treating infectious and immune-mediateddiseases. Dr. Fauci also serves as one of the key advisors tothe White House and Department of Health and HumanServices on global AIDS issues, and on initiatives to bolstermedical and public health preparedness against emerginginfectious disease threats such as pandemic influenza. Hewas one of the principal architects of the President’sEmergency Plan for AIDS Relief (PEPFAR), which has helpedsave millions of lives throughout the developing world.Dr. Fauci also is the long-time chief of the NIAIDLaboratory of Immunoregulation. He has made manycontributions to basic and clinical research on the
pathogenesis and treatment of immune-mediated andinfectious diseases. He helped pioneer the field of humanimmunoregulation by making important basic scientificobservations that underpin the current understanding of theregulation of the human immune response. In addition, Dr.Fauci is widely recognized for delineating the precisemechanisms whereby immunosuppressive agents modulatethe human immune response. He developed effectivetherapies for formerly fatal inflammatory and immunemediated diseases such as polyarteritis nodosa,granulomatosis with polyangiitis (formerly Wegener'sgranulomatosis), and lymphomatoid granulomatosis.Dr. Fauci has made seminal contributions to theunderstanding of how HIV destroys the body's defensesleading to its susceptibility to deadly infections. Further, hehas been instrumental in developing highly effectivestrategies for the therapy of patients living with HIV/AIDS, aswell as for a vaccine to prevent HIV infection. He continuesto devote much of his research time to identifying the natureof the immunopathogenic mechanisms of HIV infection andthe scope of the body's immune responses to HIV.Dr. Fauci is a member of the US National Academy ofSciences and is the recipient of numerous prestigious awardsfor his scientific and global health accomplishments,including the National Medal of Science, the Robert KochMedal, the Mary Woodard Lasker Award for Public Service,and the Presidential Medal of Freedom. He has beenawarded 43 honorary doctoral degrees and is the author,coauthor, or editor of more than 1,290 scientificpublications, including several major textbooks.
Carl W. DieffenbachDr. Carl W. Dieffenbach is theDirector of the Division of AIDSat the National Institute ofAllergy and Infectious Diseases,part of the National Institutes ofHealth. Under his leadership,the Division supports a globalresearch portfolio to advancebiological knowledge ofHIV/AIDS, its related coinfections, and co-morbidities. With the ultimate goal ofcreating an “AIDS-free Generation,” the Division developsand supports the infrastructure and biomedical researchneeded to: 1) halt the spread of HIV through thedevelopment of an effective vaccine and biomedicalprevention strategies that are safe and desirable; 2) developnovel approaches for the treatment and cure of HIVinfection; 3) treat and/or prevent co-infections such astuberculosis, and co-morbidities of greatest significance; and4) foster partnerships with scientific and communitystakeholders to develop and implement effectiveinterventions. Dr. Dieffenbach received his bachelor’s degreein biochemistry from the University of Maryland in 1976 andhis Ph.D. in biophysics from The Johns Hopkins University in1984.
Kenneth H. MayerDr. Kenneth Mayer is a Professorat the Harvard Medical Schooland the Harvard T.C. Chan Schoolof Public Health, an AttendingPhysician at Beth Israel DeaconessMedical Center in Boston andDirector of HIV PreventionResearch there. He is the founder,Co-Chair and Medical ResearchDirector of The Fenway Institute,the research, training and health policy division of FenwayHealth, the largest ambulatory facility caring for HIV-infectedpatients in New England. Dr. Mayer has served on thenational boards of HIVMA, amfAR, GLMA. He is a member ofthe Governing Council of the International AIDS Society, andis a member of the Scientific Advisory Board of PEPFAR. He isone of the Principal Investigators of the NIH-funded HarvardHIV/AIDS Clinical Trial Unit, and has led trials in the HPTN,HVTN and MTN. He is currently studying how to optimizePrEP adherence with support from NIMH. He is the coauthor of more than 700 peer-reviewed publications. He wasbeen a Section Editor for Clinical Infectious Diseases, and iscurrently an Associate Editor of AIDS Patient Care and STDs,and on the Editorial Boards of AIDS and JIAS. He was theeditor of three texts related to the impact of AIDS on diversedisciplines, as well as “The Social Ecology of InfectiousDiseases” (Academic Press) and is Associate Editor of TheFenway Guide to LGBT Health (ACP Press). He continues toteach and mentor medical students, residents, and fellows.
Sharon L. HillierSharon L. Hillier, Ph.D., is amicrobiologist whose research hasfocused on understanding boththe preventive and causative rolesthat certain microorganisms in thevagina have with respect togenital tract infections, sexuallytransmitted infections (STIs)including HIV and pre-term birth,and on the evaluation of topicalmicrobicides for prevention of STIs. At the University ofPittsburgh, Dr. Hillier is the Richard Sweet Professor ofReproductive Infectious Disease and vice chair for facultyaffairs in the department of obstetrics, gynecology andreproductive sciences. In addition, she holds secondaryappointments in the department of microbiology andmolecular genetics. Dr. Hillier has been recognized twice bythe American Sexually Transmitted Diseases Association(ASTDA) as the recipient of the ASTDA Achievement Awardin 1996 and the Thomas Parran Award in 2009. Hercontributions to women’s health were recognized by herpeers with the 2007 Award for Outstanding Contributions tothe Field of Infectious Diseases in Obstetrics and Gynecologyfrom the Infectious Diseases Society for Obstetrics andGynecology. She has a strong record of service, as the chairof the NIH Office of AIDS Research (OAR) Advisory Councilfrom 2010-2103, and is currently on NIH’s AIDS ResearchAdvisory Council. She currently serves on the InternationalSociety for STD Research Foundation Board and on theEditorial Board for Sexually Transmitted Diseases.
Raphael J. LandovitzRaphael J. Landovitz’s clinicalresearch career focuses onoptimizing the use of HIVantiretroviral therapy for both HIVtreatment and HIV prevention.Dr. Landovitz was trainedat Princeton University andHarvard Medical School. Hecompleted post-graduate trainingin internal medicine at Brighamand Women’s Hospital (1996-1999) and Infectious Diseasesand HIV Medicine at Brigham and Women’s Hospital andMassachusetts General Hospital (1999-2001). He served asChief Medical Resident at the Brigham and Women’sHospital from 2001-2002. He served on the faculty of theDivision of Infectious Diseases at the Brigham and Women’sHospital from 2001-2005, and then as Medical Co-Director ofthe Vietnam CDC-Harvard Medical School AIDS Partnership.He is Currently Associate Professor of Medicine in theDivision of Infectious Diseases at UCLA, Associate Director ofthe UCLA Center for Clinical AIDS Research & Education, andCo-Director of the UCLA Center for HIV Identification,Prevention, and Treatment Services (CHIPTS). He is leadingthe NIH/DAIDS funded Phase 2a and Phase 3 studies of longacting injectable PrEP using cabotegravir (GSK 1265744). Hewas awarded the John Carey Young Investigator Award bythe AIDS Clinical Trials Group in 2010.
Kenneth A. FreedbergKenneth A. Freedberg isProfessor of Medicine at HarvardMedical School andMassachusetts General Hospital(MGH) and Director of theMedical Practice EvaluationCenter at MGH. He also directsthe Program in Epidemiology andOutcomes Research at theHarvard University Center forAIDS Research and is one of the founding directors of theCost-effectiveness of Preventing AIDS Complications (CEPAC)research group. His research focus is on HIV, TB, STDs, aswell as other chronic diseases including cardiovasculardisease, substance use disorders, and genomics andprecision medicine. He utilizes the methods of costeffectiveness analysis, clinical epidemiology, andimplementation science, and has ongoing studies in theUnited States as well as in France, Spain, Estonia, Brazil,South Africa, Côte d’Ivoire, Zimbabwe, Botswana,Mozambique, and India. This NIH-funded research examinespolicies for HIV testing, antiretroviral use, laboratorymanagement, PrEP, and HIV/TB co-infection. He has aparticular interest in informing guidelines in countries andregions in both well-resourced and more resource-limitedsettings.
Doug KrakowerDr. Doug Krakower is anAttending Physician in theDivision of Infectious Diseases atBeth Israel Deaconess MedicalCenter in Boston, Adjunct Facultyat the Fenway Institute, andAssistant Professor of Medicine atHarvard Medical School. Hisresearch focuses on ways tooptimize HIV prevention in caresettings. Currently, he is conducting studies with fundingfrom the National Institutes of Health to enhance patientprovider communication and clinical decision makingregarding the use of pre-exposure prophylaxis. He is alsoAffiliated Faculty at the Ratelle STD/HIV Prevention TrainingCenter of the Massachusetts Department of Public Health.His clinical practice encompasses general infectious diseasesand HIV treatment and prevention.
Brenda Gati MirembeDr. Brenda Gati Mirembe is aninvestigator at Makerere UniversityJohn Hopkins University (MU-JHU)Research Collaboration in Uganda.She is a recognized researcher in fieldof HIV prevention and has been partof the research team as medicalofficer and/or study coordinator forseveral microbicide research studiessince 2005 namely; CelluloseSulphate, MTN001, MTN003 (VOICE),MTN003B, MTN020 (ASPIRE) Mirembe’s interests are inadolescent and women’s health mainly in STI/HIV preventionto include improvement in reproductive health andcontraception. Dr. Mirembe holds a Bachelor of Medicineand Surgery (MBChB) from Makerere University, Uganda anda Master’s of Science in Epidemiology (MSc Epi) fromUniversity of London, UK.David Goodman-MezaDavid Goodman-Meza, MDreceived his medical degreefrom Universidad Autónoma deBaja California in Tijuana,Mexico. He completed aMaster’s of Advanced Sciencedegree program in ClinicalResearch at the University ofCalifornia San Diego andsubsequently a NIH T32-funded Post-Doc at UCSD’s Divisionof Global Public Health. He went on to complete Internal
Medicine training at Jacobi Medical Center/Albert EinsteinCollege of Medicine, located in the Bronx, NY and is currentlyan Infectious Diseases fellow at the University of CaliforniaLos Angeles. His current research interest is in biomedicalprevention of HIV among underserved and substanceabusing populations.Scott Dryden-PetersonScott Dryden-Peterson isan Attending Physician inInfectious Diseases atBrigham and Women’sHospital and a ResearchAssociate at theBotswana Harvard AIDSInstitute Partnership andthe Harvard T.H. ChanSchool of Public Health.His primary focus is directed at the clinical and epidemiologicinvestigation of HIV and its complications in entrenchedepidemics. He has conducted research in an African contextfor over 10 years. His projects include research related tothe delivery of care to HIV-infected pregnant women inBotswana and to improving outcomes for the largely HIVuninfected infants born to these women. He is aninvestigator in a large community randomized trial inBotswana evaluating the test-and-treat hypothesis toextinguish the epidemic. He is co-founder of BotswanaOncology Global Outreach (BOTSOGO) and leads a numberof clinical, translational, and epidemiologic projectsevaluating the role of HIV in the incidence and outcomes ofcancer.
Susan Cu-UvinDr. Susan Cu-Uvin is Professor ofObstetrics and Gynecology andMedicine at the Alpert School ofMedicine, Brown University andProfessor of Health Services,Policy and Practice at the Schoolof Public Health . She is theDirector of the Brown GlobalHealth Initiative. She is thedirector of the Providence/BostonUniversity Center for AIDS Research (CFAR). She chairs theInter CFAR HIV in Women working group. She was thePrincipal Investigator of the Brown/Tufts AIDS InternationalTraining Research Program (AITRP) which ran for 20 years.She was the Director of the Immunology Center at theMiriam Hospital, a clinic that serves 1,600 HIV infectedpatients from 1999-2009. She chaired the Women’s HealthCommittee of the Adult AIDS Clinical Trials Group (ACTG)from 2003-2006. She has been NIH funded since 1996 andhas been the Principal Investigator of several RO1s to assessHIV dynamics in the female genital tract. She was a coinvestigator of the CDC funded study to understand thenatural history of HIV in women (HERS) and the study tounderstand the natural history of HIV and AIDS in the era ofhighly active antiretroviral therapy (SUN). She had a K24Mid-Career Investigator Award in Patient Oriented Researchwhich allowed her to mentor several junior investigatorslocally as well as internationally. She is a co-investigator inmicrobicide studies and mucosal immunity in the femalegenital tract. She served on the Institute of Medicine’sCommittee on Perinatal Transmission of HIV, Committees on
Women’s Health research and HIV Testing and Access toCare. She is a member of the Public Health Service TaskForce/Perinatal Antiretroviral Guidelines Working Group,and the NIH advisory committee on HIV related research inwomen and girls. She chairs the HPV Working Group,USPHS/IDSA Guidelines for the Prevention and Treatment ofOpportunistic Infections. She has been a member of severalNIH review committees and chaired the NIH review onresearch training for junior faculty in Medical EducationPartnerships Initiative Institutions (MEPI) in Africa.Maureen M. GoodenowMaureen M. Goodenow,Ph.D., is NIH AssociateDirector for AIDS Researchand Director of the NIH Officeof AIDS Research (OAR). Dr.Goodenow brings more than25 years of experience inHIV/AIDS research andadvocacy to the position. Shejoined NIH in July 2016 tolead OAR’s initiatives, working closely with the NIH institutesand centers, to pursue new tools for preventing HIVinfection including a vaccine, improved treatments, andultimately, a cure.Dr. Goodenow has previously served NIH on multipleNIH advisory committees, including the AIDS ResearchAdvisory Committee for the Division of AIDS at the NationalInstitute of Allergy and Infectious Diseases, and the OARadvisory committee for the Trans-NIH Plan for HIV-RelatedResearch. She also advised a joint program between NIH and
the U.S. Department of State to enhance research betweenU.S. and Russian scientists, and advised the FogartyInternational Center on programs in India and Kazakhstan.Recently, Dr. Goodenow played an important role ininternational AIDS efforts as the Acting Director of the Officefor Research and Science within the U.S. Department ofState, Office of the U.S. Global AIDS Coordinator and Officeof Global Health Diplomacy. There she oversaw combinationprevention trials funded by the U.S. President’s EmergencyPlan for AIDS Relief (PEPFAR). She also served from 20122013 as a senior science advisor and Jefferson Science Fellowin the Department of State Bureau of East Asian and PacificAffairs, Office of Economic Policy.Prior to joining OAR, Dr. Goodenow held the positionof Professor of Pathology, Immunology, and LaboratoryMedicine at the University of Florida where she held theStephany W. Holloway Endowed University Chair forHIV/AIDS Research. Dr. Goodenow received a Ph.D. from theAlbert Einstein College of Medicine, was a postdoctoralfellow at the Sloan-Kettering Institute, and a visiting scientistat the Pasteur
Speakers’ Biographies Bruce D. Walker Dr. Bruce D. Walker is the Director of the Ragon Institute of MGH, MIT and Harvard, a Professor of Medicine at Harvard Medical School, a Professor of Practice at MIT and a Howard Hughes Medical Institute Investigator. In addition to his clinical duties as a board certified Infectious Disease specialist, his
Polk Audio Speakers System Manual Author: CARiD Subject: Polk Audio Speakers System Manual Keywords: speakers, car speakers, best speakers, speaker system, speaker grilles, full range speakers, automotive speakers, coaxial speakers, stereo speakers, 3-way speakers, sound bars, speaker boxes, speaker kits, tweeters Created Date: 4/5/2014 7:44:42 PM
Life science graduate education at Harvard is comprised of 14 Ph.D. programs of study across four Harvard faculties—Harvard Faculty of Arts and Sciences, Harvard T. H. Chan School of Public Health, Harvard Medical School, and Harvard School of Dental Medicine. These 14 programs make up the Harvard Integrated Life Sciences (HILS).
Biographies Keynote speakers and panellists Organised by the EU Agencies Network. More info on euagencies.eu or by email Coordination-EU-Agencies@euipo.europa.eu. 2 Bios of keynote speakers and panellists . Keynote speakers António Campinos, Executive Director, EUIPO . António Campinos (48) has been head of the EUIPO (formerly OHIM) since 1 October 2010. A native of Portugal, he studied law .
1. AGENCY USE ONLY (Leave Blank) 2. REPORT DATE 3. REPORT TYPE AND DATES COVERED IMay 1993 Inte 'rim Jan 92 -Se2 92 4. TITLE AND SUBTITLE 5. FUNDING NUMBERS INTELLIGENT USE OF CFAR ALGORITHMS C -F30602-91-C-0017 6,.AUTHOR( ) p. Antonik, B. Bowles, G. Caparo, L. Hennington, PR TA -4506-11
Kubernetes Eirini enables pluggable scheduling for CFAR (allows operators to choose whether CFAR should use Diego or Kubernetes to orchestrate application container instances) Stratos is a web UI for managing Cloud Foundry and other pluggable API endpoints. It allow
Finance and Accounting Research (WFA-CFAR) will be a catalyst for enhancing finance and accounting research and education, which benefits faculty members, students, and businesses. To that end, initiatives housed under the WFA-CFAR umbrella include: Specialized master’s degree programs in
Sciences at Harvard University Richard A. and Susan F. Smith Campus Center 1350 Massachusetts Avenue, Suite 350 Cambridge, MA 02138 617-495-5315 gsas.harvard.edu Office of Diversity and Minority Affairs minrec@fas.harvard.edu gsas.harvard.edu/diversity Office of Admissions and Financial Aid admiss@fas.harvard.edu gsas.harvard.edu/apply
Alfredo Lopez Austin/ Leonardo Lopeb anz Lujan,d Saburo Sugiyamac a Institute de Investigaciones Antropologicas, and Facultad de Filosofia y Letras, Universidad Nacional Autonoma de Mexico bProyecto Templo Mayor/Subdireccion de Estudios Arqueol6gicos, Instituto Nacional de Antropologia e Historia, Mexico cDepartment of Anthropology, Arizona State University, Tempe, AZ 85287-2402, USA, and .
